Evidence map›Paper›PMID 39829810›Full record

ArticlebioRxiv : the preprint server for biology2025

Exosomes derived from highly scalable and regenerative human progenitor cells promote functional improvement in a rat model of ischemic stroke.

Jieun Lee, Susanna R Var, Derek Chen, Dilmareth E Natera-Rodriguez, Mohammad Hassanipour, Michael D West, Walter C Low, Andrew W Grande, Dana Larocca

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jieun LeeUniverXome Bioengineering, Inc., (formerly known as AgeX Therapeutics Inc.), Alameda, California, USA.ORCID 0000-0002-1486-012X
Susanna R VarDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Derek ChenDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Dilmareth E Natera-RodriguezDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Mohammad HassanipourUniverXome Bioengineering, Inc., (formerly known as AgeX Therapeutics Inc.), Alameda, California, USA.
Michael D WestUniverXome Bioengineering, Inc., (formerly known as AgeX Therapeutics Inc.), Alameda, California, USA.
Walter C LowDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Andrew W GrandeDepartment of Neurosurgery, University of Minnesota, Minneapolis, Minnesota, USA.
Dana LaroccaUniverXome Bioengineering, Inc., (formerly known as AgeX Therapeutics Inc.), Alameda, California, USA.

Funding

Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating StrokeR41NS105263 · NINDS · SERINA THERAPEUTICS, INC. · PI GRANDE, ANDREW W, LEE, JI EUN · 2018 to 2018
$386k
Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery DiseaseR41HL170875 · NHLBI · SERINA THERAPEUTICS, INC. · PI HUANG, NGAN F., LEE, JI EUN · 2023 to 2023
$341k
NHLBI NIH HHS R41 HL170875NINDS NIH HHS R41 NS105263
6 · The paper itself

Abstract

Globally, there are 15 million stroke patients each year who have significant neurological deficits. Today, there are no treatments that directly address these deficits. With demographics shifting to an older population, the problem is worsening. Therefore, it is crucial to develop feasible therapeutic treatments for stroke. In this study, we tested exosomes derived from embryonic endothelial progenitor cells (eEPC) to assess their therapeutic efficacy in a rat model of ischemic stroke. Importantly, we have developed purification methods aimed at producing robust and scalable exosomes suitable for manufacturing clinical grade therapeutic exosomes. We characterized exosome cargos including RNA-seq, miRNAs targets, and proteomic mass spectrometry analysis, and we found that eEPC-exosomes were enhanced with angiogenic miRNAs (i.e., miR-126), anti-inflammatory miRNA (i.e., miR-146), and anti-apoptotic miRNAs (i.e., miR-21). The angiogenic activity of diverse eEPC-exosomes sourced from a panel of eEPC production lines was assessed

Indexed as

eEPC-exosomesembryonic endothelial progenitor cells (eEPCs)exosomesStroke

Identifiers

PMID39829810
PMCPMC11741374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.